Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urologic Endoscopic Procedure: Cystoscopic Examination01:28

Urologic Endoscopic Procedure: Cystoscopic Examination

Meaning of Cystoscopic Examination:Cystoscopy is an essential diagnostic tool in urology that is used to assess the structure and function of the genitourinary system. It provides a direct view of the urethra, bladder, and, in some cases, the ureteral openings. This procedure helps detect structural abnormalities, infections, cancers, and blockages in the urinary tract. There are two types of cystoscopy:Flexible cystoscopy is commonly performed in outpatient settings due to its less invasive...
Imaging Studies VI: Voiding Cystourethrography and Cystography01:22

Imaging Studies VI: Voiding Cystourethrography and Cystography

Voiding Cystourethrography (VCUG) and Cystography are specialized radiographic procedures used to examine the structure and function of the bladder and urethra.Voiding Cystourethrography (VCUG)A Voiding Cystourethrogram (VCUG) is a diagnostic imaging procedure that assesses the anatomy and function of the lower urinary tract. It focuses on the bladder, bladder neck, and urethra, helping detect abnormalities such as vesicoureteral reflux (VUR)—the backward or reverse flow of urine into the...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Gallbladder01:17

Gallbladder

The gallbladder is a small, pear-shaped organ that plays a crucial role in our digestive system. Measuring about 10 cm in length, it is comparable in size to a kiwi fruit and is located in a hollow area on the lower surface of the liver. The gallbladder's primary function is to store and concentrate bile, a fluid produced by the liver that aids in digestion.
The gallbladder's anatomy consists of three regions: the fundus, body, and neck. Extending from the neck, the cystic duct joins the common...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GLUT9b- and ABCG2-mediated collecting duct urate transport uncover a vasopressin-independent mechanism of renal water reabsorption.

The Journal of clinical investigation·2026
Same author

Towards precision medicine for brain arteriovenous malformations.

The Journal of clinical investigation·2026
Same author

Purine Metabolism Regulates the Severity of APOL1 Nephropathy.

Journal of the American Society of Nephrology : JASN·2026
Same author

De Novo <i>TRIO</i> Missense Variants Disrupt Ras-GEF Domains and Cause Congenital Ventriculomegaly and Hydrocephalus.

Human mutation·2026
Same author

Deep secretome analysis reveals the effects of LiCl on fibroangiogenic remodeling in coculture and mouse models of peritoneal dialysis.

Science signaling·2026
Same author

Local Immunometabolic Intervention With Alanyl-Glutamine Resolves Peritoneal Dialysis-Induced Immune Cell Dysfunction.

Kidney international reports·2026
Same journal

KDIGO Life Cycle of Guideline Development Series Part 6: Bridging the Gap between Guidelines and Clinical Practice: The KDIGO Approach to Global Implementation and Education in Nephrology.

Kidney international·2026
Same journal

KDIGO Life Cycle of Guideline Development Series Part 5: Guideline updates and a living model for the future.

Kidney international·2026
Same journal

Crystal-storing histiocytosis causing severe acute kidney injury.

Kidney international·2026
Same journal

Peritoneal dialysis in a patient with extensive burn scarring.

Kidney international·2026
Same journal

COPA syndrome unmasked by anti-neutrophil cytoplasmic antibody-positive immune-complex nephritis.

Kidney international·2026
Same journal

Monitoring anti-nephrin antibodies in the management of recurrent diffuse podocytopathy.

Kidney international·2026
See all related articles

Related Experiment Video

Updated: Jul 2, 2026

Generation and Quantitative Characterization of Functional and Polarized Biliary Epithelial Cysts
09:55

Generation and Quantitative Characterization of Functional and Polarized Biliary Epithelial Cysts

Published on: May 16, 2020

Let's look at cysts from both sides now.

Seth L Alper1

  • 1Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. salper@bidmc.harvard.edu

Kidney International
|August 30, 2008
PubMed
Summary
This summary is machine-generated.

Researchers identified a new way to slow autosomal-dominant polycystic kidney disease (ADPKD) cyst growth. Inhibiting the KCa3.1 channel with a small molecule offers a promising therapeutic strategy for ADPKD patients.

More Related Videos

Endoscopic Approach for Colloid Cyst Resection
02:30

Endoscopic Approach for Colloid Cyst Resection

Published on: May 23, 2025

Microscopic Cyst Resection for the Treatment of Patients Diagnosed with Epididymal Cyst
03:10

Microscopic Cyst Resection for the Treatment of Patients Diagnosed with Epididymal Cyst

Published on: March 31, 2023

Related Experiment Videos

Last Updated: Jul 2, 2026

Generation and Quantitative Characterization of Functional and Polarized Biliary Epithelial Cysts
09:55

Generation and Quantitative Characterization of Functional and Polarized Biliary Epithelial Cysts

Published on: May 16, 2020

Endoscopic Approach for Colloid Cyst Resection
02:30

Endoscopic Approach for Colloid Cyst Resection

Published on: May 23, 2025

Microscopic Cyst Resection for the Treatment of Patients Diagnosed with Epididymal Cyst
03:10

Microscopic Cyst Resection for the Treatment of Patients Diagnosed with Epididymal Cyst

Published on: March 31, 2023

Area of Science:

  • Nephrology
  • Molecular Biology
  • Pharmacology

Background:

  • Autosomal-dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by kidney cyst formation and enlargement.
  • Current therapeutic strategies for ADPKD are limited, highlighting the need for novel treatment approaches.
  • Understanding the genetic basis of ADPKD has accelerated the development of potential therapies.

Discussion:

  • Albaqumi and colleagues investigated the role of the basolateral KCa3.1 K(+) channel in ADPKD cystogenesis.
  • Inhibition of the KCa3.1 channel with a small molecule demonstrated a significant reduction in cyst enlargement in preclinical models.
  • This approach targets a key mechanism of cyst fluid accumulation, offering a new avenue for ADPKD treatment.

Key Insights:

  • The KCa3.1 channel is a viable therapeutic target for slowing ADPKD progression.
  • A nontoxic small molecule inhibitor of KCa3.1 has been identified, with a closely related compound ready for clinical trials.
  • Blocking cyst fluid accumulation from both apical and basolateral sides presents a comprehensive therapeutic strategy.

Outlook:

  • Further clinical development of KCa3.1 inhibitors is anticipated to translate this finding into patient therapy.
  • This research contributes to the rapidly decreasing lag time between ADPKD gene discovery and therapeutic application.
  • The identification of druggable targets like KCa3.1 channel offers hope for improved management of ADPKD.